CLM-103 selected as a government project by Korea Drug Development Fund

Opening of Cell and Gene Therapy Manufacturing Facility (CGT Center)

CLM-103 Patent registration

Relocated Headquarters (Jeongneung-dong, Mediscience Park)

CLM-103 IND approved

Series B Inviting investment

CLM-103 China patent registration

CLM-103 Canada patent registration

CLM-103 US patent registration

CLM-103 Europe patent registration Signed joint R&D agreement with UNSW(The University of New South Wales), Australia

Signed a joint R&D business agreement with the Korea University's College of Medicine

Signed a business agreement for the development of anticancer immunotherapy (SG Medical)

CLM-103 Japan patent registration

CLM-103 Russia patent registration CLM-103 Australia patent registration

Acquired Venture Business certification

Acquired certification as a Company Affiliated Research Institute

YYB-101 Phase 2 approved Series A Inviting investment

Established CellabMED Co., Ltd. (spun off from Yooyoung Pharmaceuticals Bio Research Institute)

Completed YYB-101 Phase 1 Clinical Trial

Designated project for the Anti-Cancer Drug Development Group

Started Yooyoung Bio Research Institute